| |
| |
|
| Insider
Information: |
Goldberg Mark Alan |
| Relationship: |
|
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
79,501 |
|
|
Indirect Shares
|
11,497 |
|
|
| Direct
Value |
$1,729,577 |
|
|
|
Indirect Value
|
$3,065 |
|
|
| Total
Shares |
90,998 |
|
|
| Total
Value |
$1,732,642 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -26.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immunogen Inc |
IMGN |
Director |
2024-02-12 |
0 |
|
0 |
Premium* |
|
|
Synageva BioPharma Corp |
GEVA |
|
2014-09-19 |
562 |
2013-01-02 |
0 |
Premium* |
|
|
Glycomimetics Inc |
GLYC |
|
2024-03-29 |
24,828 |
2024-03-29 |
11,497 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
Director |
2021-01-04 |
38,099 |
2018-12-19 |
0 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
|
2023-06-21 |
16,012 |
2020-06-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IMGN |
Immunogen Inc |
Director |
– • – |
2011-11-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
800 |
|
- |
|
| GLYC |
Glycomimetics Inc |
Director |
– • – |
2014-07-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,100 |
|
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,312 |
1,312 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
3,562 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
5,250 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
5,812 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
|
– • – |
2022-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,600 |
13,412 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
|
– • – |
2023-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,600 |
16,012 |
0 |
- |
|
| IMGN |
Immunogen Inc |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,720) |
0 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP, Product Development |
• – – |
2013-01-02 |
4 |
OE |
$0.95 |
$4,196 |
D/D |
4,417 |
4,417 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP, Product Development |
• – – |
2013-02-01 |
4 |
OE |
$0.95 |
$4,196 |
D/D |
4,417 |
4,417 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP, Product Development |
• – – |
2013-03-01 |
4 |
OE |
$0.95 |
$4,196 |
D/D |
4,417 |
4,417 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP,Medical&Regulatory Affairs |
• – – |
2013-04-01 |
4 |
OE |
$0.95 |
$4,195 |
D/D |
4,416 |
4,416 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-06-11 |
4 |
OE |
$0.95 |
$165,513 |
D/D |
21,597 |
22,056 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2020-04-01 |
4 |
A |
$1.28 |
$13,734 |
D/D |
10,730 |
20,730 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
Director |
– • – |
2023-09-30 |
4 |
A |
$1.50 |
$13,751 |
D/D |
9,167 |
14,417 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2020-07-01 |
4 |
A |
$1.79 |
$13,874 |
D/D |
7,751 |
28,481 |
0 |
- |
|
| IMGN |
Immunogen Inc |
Director |
– • – |
2016-12-15 |
4 |
B |
$1.80 |
$36,000 |
D/D |
20,000 |
23,800 |
2.39 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2020-10-01 |
4 |
A |
$2.25 |
$13,874 |
D/D |
6,166 |
34,647 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$13,752 |
D/D |
5,827 |
20,244 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$13,752 |
D/D |
4,584 |
24,828 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2018-12-19 |
4 |
B |
$3.19 |
$31,897 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2021-01-04 |
4 |
A |
$4.02 |
$13,877 |
D/D |
3,452 |
38,099 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
Director |
– • – |
2016-03-04 |
4 |
B |
$4.77 |
$49,630 |
D/D |
10,397 |
11,497 |
2.39 |
- |
|
| IMGN |
Immunogen Inc |
Director |
– • – |
2018-11-06 |
4 |
B |
$5.76 |
$172,800 |
D/D |
30,000 |
53,800 |
2.39 |
- |
|
64 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
